Organization
Institut de Cancérologie de l'Ouest, Angers, France
8 abstracts
Abstract
Prediction of pathological response to neo-adjuvant chemotherapy using texture parameters of initial 18-FDG PET/CT in estrogen receptor positive/Her2 negative (ER+/HER2-) early breast cancer (eBC).Org: Institut de Cancérologie de l'Ouest, Angers, France, Institut de Cancérologie de l'Ouest, Saint-Herblain, France, Institut de Cancérologie de l'Ouest, France, France, Institut de Cancérologie de l'Ouest-René Gauducheau, Centre de Recherche en Cancérologie, Saint-Herblain, France, Institut de Cancerologie de l'Ouest, Saint-Herblain, France,
Abstract
Impact of first-line immunotherapy on survival and intracranial outcomes from a real-world cohort of non-small cell lung cancer patients with brain metastases at diagnosis.Org: Nantes University Hospital, Institut de Cancérologie de l'Ouest, Angers, France, Nantes Université, CHU Nantes-Department of Hepato-Gastroenterology, Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance,
Abstract
Immunotherapy for localized dMMR/MSI tumors: First interim analysis of the IMHOTEP trial.Org: Centre Leon Berard, Lyon I University, Hôpital Européen Georges Pompidou, Sorbonne University and Saint-Antoine Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study.Org: Institut de Cancerologie de l'Ouest, Saint-Herblain, France, Gustave Roussy Cancer Center, ICO Institut de Cancerologie de l'Ouest, Oscar Lambret Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Angers, France,
Abstract
PEMBROCABOSARC: Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas.Org: Institut Bergonie, Institut Bergonié, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Institut Paoli Calmettes, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy,
Abstract
Real-life efficacy of nivolumab plus ipilimumab combination in untreated, unresectable malignant pleural mesotheliomas: Result of French early access program—MESOIMMUNE – GFPC 04-2021.Org: HIA SAINTE ANNE, Univ Rouen Normandie, LITIS Lab QuantIF team EA4108, CHU Rouen, Inserm CIC-CRB 1404,
Abstract
Early palliative care for patients with metastatic upper gastrointestinal cancers: A survival analysis of the EPIC randomized trial.Org: Institut du Cancer de Montpellier, Centre Oscar Lambret, Institut de Cancérologie de l'Ouest, Angers, France, Digestive Oncology, Hopital Duchenne, Medical Oncology Department, Lille University Hospital, University of Lille, Lille, France,
Abstract
Prognostic impact of TP53 mutations in metastatic non-squamous non-small-cell lung cancer.Org: Institut de Cancérologie de l'Ouest, Angers, France, Nantes University Hospital, Nantes Université, CHU Nantes-Department of Hepato-Gastroenterology, Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance,